Loading company…
N1 Life develops peptide-drug conjugates and drug delivery technologies for therapeutics.
Founded in 2021, N1 Life develops therapeutics using drug delivery technologies and peptide-drug conjugates. Its Absotride platform includes a peptide transporter, linker and payload drugs, and its Meta Tide peptide is designed to target the tumor microenvironment. The company is based in Suzhou, China, with additional US offices. In April 2023, Legend Capital led its pre-Series A funding, joined by China Medical System Holdings, Sino-Singapore Suzhou Industrial Park Industrial Investment, Haoping Investment and Frees Fund.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in